Pancoast tumor

Reading File

Finding Sources

Searching PubMed

Pancoast tumor superior sulcus

Reading File

Finding Sources

Reading File

Here is a comprehensive overview of Pancoast tumor synthesized from Gray's Anatomy for Students, Robbins & Kumar Basic Pathology, Murray & Nadel's Textbook of Respiratory Medicine, and Schwartz's Principles of Surgery.

Pancoast Tumor (Superior Sulcus Tumor)

Definition and Location

A Pancoast tumor is a bronchogenic carcinoma originating from the superior part of the oblique fissure of the lung, extending superiorly to involve the apex of the lung and adjacent structures. The designation applies specifically to tumors involving the parietal pleura or deeper structures overlying the first rib - chest wall involvement at or below the second rib does not qualify as a Pancoast tumor. The apex of the lung rises approximately 2.5 cm above the medial third of the clavicle, placing it in close proximity to critical neurovascular structures.

The term was coined by Henry Pancoast, who described the syndrome in 1932.

Gray's Anatomy for Students, p. 295
Schwartz's Principles of Surgery, p. 1938

Histology

The vast majority are non-small cell lung carcinoma (NSCLC) - most commonly squamous cell carcinoma. Small cell lung carcinoma (SCLC) and other tumor types can rarely present this way. The histologic pattern doesn't differ from lung cancer elsewhere; the clinical syndrome is defined by location and local extension, not cell type.

Murray & Nadel's Textbook of Respiratory Medicine

Pancoast Syndrome

Pancoast syndrome is present in roughly one-third of patients with superior sulcus tumors. The classic triad arises from invasion of adjacent structures:

1. Shoulder and Arm Pain (most common initial symptom)

Results from tumor involvement of the parietal pleura, brachial plexus (C8-T1-T2), vertebral bodies, and first/second/third ribs
Pain radiates along the upper back or shoulder into the axilla, and along the ulnar nerve distribution (ring and little fingers - C8/T1)
Patients are frequently misdiagnosed with shoulder arthritis or bursitis for months before the correct diagnosis is made

2. Horner Syndrome (MAP mnemonic)

Miosis - constriction of the pupil (loss of dilator pupillae innervation)
Anhidrosis - absence of sweating on the ipsilateral face
Ptosis - partial drooping of the upper eyelid (loss of smooth muscle component of levator palpebrae)

The cause is disruption of the cervical sympathetic chain. The tumor invades the cervicothoracic (stellate) ganglion, which is formed by the fusion of the inferior cervical ganglion (at the level of the C7 transverse process) with the first thoracic ganglion.

3. Hand Weakness and Atrophy

Intrinsic hand muscles become weak and atrophied as the tumor progresses
Mediated by C8/T1 involvement (ulnar nerve distribution for most intrinsic hand muscles)
Absence of the triceps brachii reflex indicates involvement of the C7 anterior ramus / middle trunk of the brachial plexus

With further extension through intervertebral foramina: spinal cord compression and paraplegia can develop.

Gray's Anatomy for Students, pp. 295-296
Murray & Nadel's, p. 1745

Diagnosis and Imaging

Modality	Role
Chest X-ray	May show apical mass; may be negative
CT chest	Extent of tumor, mediastinal adenopathy, other nodules; first-line if CXR negative
MRI (preferred)	Superior for evaluating pleural/subpleural fat invasion, brachial plexus involvement, subclavian vessel involvement
MR angiography	Best for subclavian vessel vascular invasion
Bronchoscopy (flexible)	Diagnostic yield ~50% for apical tumors
TTNA (transthoracic needle aspiration)	Diagnostic yield >90%, even if bronchoscopy nondiagnostic

Murray & Nadel's, p. 1746

Staging

Superior sulcus tumors are staged as T3N0M0 (Stage IIB) or higher:

T3 or T4 based on tumor size and extent of invasion
Stage IIB (25%), Stage IIIA (22%), Stage IIIB (53%) in large series from MD Anderson
One-third to one-half of all superior sulcus tumors have identifiable distant metastasis at diagnosis

Poor prognostic factors:

Weight loss
Vertebral body or supraclavicular involvement
N1 or N2 nodal involvement
Incomplete resection

Treatment

Surgical Eligibility

Surgery should only be performed in patients proven negative for mediastinal lymph node involvement (N2-positive disease carries high morbidity/mortality). Workup requires:

EBUS-/EUS-guided FNA if bulky adenopathy is present
Mediastinoscopy to confirm nodal status (negative FNA alone is insufficient)

Current Standard of Care: Trimodality Therapy

Neoadjuvant chemoradiotherapy followed by surgical resection

Based on the North American Intergroup Trial:

2 cycles cisplatin + etoposide + concurrent thoracic radiotherapy (45 Gy over 5 weeks)
Pathologic complete response or minimal microscopic disease in 66% of resected specimens
5-year overall survival: 44% (54% with complete resection)

A Japanese phase II trial using mitomycin + vindesine + cisplatin with concurrent RT showed 5-year survival of 56%.

Surgical Technique

Thoracotomy with en bloc resection of chest wall and vascular structures + anatomic lobectomy
Portion of the lower trunk of the brachial plexus and stellate ganglion typically resected
Chest wall reconstruction with Gore-Tex for defects involving 2+ rib segments
Brain is the most common site of relapse in localized disease
Schwartz's Principles of Surgery, pp. 1938-1945
Murray & Nadel's, p. 1746

Key Associations to Remember

Feature	Detail
Location	Lung apex, above first rib/clavicle
Most common histology	Squamous cell carcinoma (NSCLC)
Classic nerve involved	C8-T2 roots / lower trunk brachial plexus
Sympathetic disruption	Stellate (cervicothoracic) ganglion
Horner's triad	Ptosis, miosis, anhidrosis
Ulnar distribution pain	Ring and little fingers (C8/T1)
Best imaging	MRI chest
Standard treatment	Chemoradiation → surgery
5-yr survival (complete resection)	~54%

Recent evidence note: A 2025 systematic review (PMID 40651130, Lung Cancer) examined therapeutic modalities for superior sulcus tumors - this aligns with the trimodality approach described above and does not appear to contradict current guidelines.

This is a shared conversation. Sign in to Orris to start your own chat.